Anti-KSA cancer vaccine - IDM Pharma
Alternative Names: Prostate cancer vaccine - IDMLatest Information Update: 27 Nov 2007
At a glance
- Originator IDM Pharma
- Developer Walter Reed Army Institute of Research
- Class
- Mechanism of Action Epithelial cell adhesion molecule inhibitors; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Colorectal cancer; Prostate cancer
Most Recent Events
- 27 Nov 2007 Discontinued - Phase-I for Colorectal cancer in USA (SC)
- 27 Nov 2007 Discontinued - Preclinical for Prostate cancer in USA (Injection)
- 18 Aug 2005 IDM S.A. has merged with Epimmune to form IDM Pharma